GLP-1–Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus
Open Access
- 1 October 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 36 (10) , 2125-2132
Abstract
Objective—: To assess the effects of glucagon-like peptide (GLP)-1–based therapies (ie, GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) on microvascular function in patients with type 2 diabetes mellitus. Approach and Results—: We studied 57 patients with type 2 diabetes mellitus (mean±SD age: 62.8±6.9 years; body mass index: 31.8±4.1 kg/m 2 ; HbA 1c [glycated hemoglobin] 7.3±0.6%) in an acute and 12-week randomized, placebo-controlled, double-blind trial conducted at the Diabetes Center of the VU University Medical Center. In the acute study, the GLP-1 receptor agonist exenatide (therapeutic concentrations) or placebo (saline 0.9%) was administered intravenously. During the 12-week study, patients received the GLP-1 receptor agonist liraglutide (1.8 mg daily), the dipeptidyl peptidase-4 inhibitor sitagliptin (100 mg daily), or matching placebos. Capillary perfusion was assessed by nailfold skin capillary videomicroscopy and vasomotion by laser Doppler fluxmetry, in the fasting state and after a high-fat mixed meal. In neither study, treatment affected fasting or postprandial capillary perfusion compared with placebo ( P >0.05). In the fasting state, acute exenatide infusion increased neurogenic vasomotion domain power, while reducing myogenic domain power (both P P <0.05). In the 12-week study, no effects on vasomotion were observed. Conclusions—: Despite modest changes in vasomotion, suggestive of sympathetic nervous system activation and improved endothelial function, acute exenatide infusion does not affect skin capillary perfusion in type 2 diabetes mellitus. Twelve-week treatment with liraglutide or sitagliptin has no effect on capillary perfusion or vasomotion in these patients. Our data suggest that the effects of GLP-1–based therapies on glucose are not mediated through microvascular responses.Keywords
This publication has 42 references indexed in Scilit:
- Meal-Related Increases in Microvascular Vasomotion Are Impaired in Obese IndividualsDiabetes Care, 2011
- Decreased microvascular vasomotion and myogenic response in rat skeletal muscle in association with acute insulin resistanceThe Journal of Physiology, 2009
- Obesity Blunts Microvascular Recruitment in Human Forearm Muscle After a Mixed MealDiabetes Care, 2009
- Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humansAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2008
- Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepirideAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- The Physiology of Glucagon-like Peptide 1Physiological Reviews, 2007
- Collateral damage: cardiovascular consequences of chronic sympathetic activation with human agingAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- Impaired Skin Capillary Recruitment in Essential Hypertension Is Caused by Both Functional and Structural Capillary RarefactionHypertension, 2001
- ROLE OF BLOOD FLOW IN THE REGULATION OF MUSCLEGLUCOSE UPTAKEAnnual Review of Nutrition, 1997
- Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose outputEndocrinology, 1992